ArticleCommunications medicine2025
Decreased Fc fucosylation aligns with enhanced RSV-specific antibody functionality in adults compared to young children.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decreased Fc fucosylation aligns with enhanced RSV-specific antibody functionality in adults compared to young children.Communications medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is a major cause of severe respiratory tract infections in infants and older adults. While RSV vaccines have recently been approved for older adults and pregnant women, and newborns can be protected through monoclonal antibody immunization, vaccine development for infants remains challenging. Understanding immunological differences between target groups is essential for improving vaccination strategies, but no clear correlates of protection have been identified yet. Antibody Fc-mediated effector functions may play an important role. Here, we aim to delineate RSV-specific antibody features underlying differences in antibody functionality between children and adults.
methodsIn an observational cohort of 24-month old children and adults (n = 46 per group), we assessed RSV-specific IgG/IgA levels, IgG subclasses, avidity, Fc glycosylation, neutralization, and antibody-dependent NK cell activation, cellular phagocytosis, and complement deposition using a systems serology approach including (multiplex) bead-based immunoassays, mass-spectrometry, and in vitro cellular assays.
resultsHere we show that, compared to children, antibodies from adults display enhanced functionality. Furthermore, RSV-specific antibodies display differences in avidity and glycosylation patterns between the two groups, which might relate to differences in the number of previous exposures. Importantly, our data strongly suggest that IgG Fc afucosylation drives the enhanced capacity of RSV-specific antibodies to activate NK cells in adults.
conclusionsOur data provide a detailed overview of similarities and differences between RSV-specific antibodies in children and adults. This information will support the ongoing quest for correlates of protection and the design of future vaccination strategies in different target populations.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.